1155 ET - Eli Lilly is poised to report another set of strong quarterly results and could again raise its sales and earnings targets for the full year, JPMorgan analysts say in a note. The analysts cite the continued ramp of Mounjaro internationally, as well as healthy growth in the U.S. obesity market. They also see some potential upside from the uptake of Zepbound in Medicare, which began July 1. "More broadly on the story, LLY remains our top pick with further upside to Street numbers over the next several years," especially outside the U.S., the analysts say, adding they also expect a series of upcoming catalysts that they believe will extend Lilly's leadership in the $200 billion-plus incretin market. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

July 07, 2026 11:55 ET (15:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.